Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 48
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06169891 | A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | ||
| NCT05544591 | Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis | ||
| NCT05027373 | Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection | ||
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | ||
| NCT04079374 | Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel | ||
| NCT05536726 | A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis | ||
| NCT06299982 | An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO | ||
| NCT06390774 | A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors | ||
| NCT06674525 | Evaluation of 626 in Healthy Adult Subjects | ||
| NCT05966701 | The MAD Study of SSGJ-613 in Healthy Subjects | ||
| NCT06324812 | Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis | ||
| NCT04667910 | 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) | ||
| NCT06270225 | A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. | ||
| NCT04345458 | Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis | ||
| NCT05641558 | Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis | ||
| NCT06361927 | A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients | ||
| NCT04367441 | Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects | ||
| NCT05865496 | A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps | ||
| NCT04445038 | Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection | ||
| NCT06173284 | Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis | ||
| NCT05138146 | A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma | ||
| NCT03356158 | A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer | ||
| NCT05145179 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors | ||
| NCT05193214 | A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma | ||
| NCT06639295 | A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps | ||
| NCT05584306 | A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma | ||
| NCT04527718 | Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers | ||
| NCT06323213 | Efficacy and Safety Study of 610 in Patients With Severe Asthma | ||
| NCT05588908 | A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | ||
| NCT03980379 | Pharmacokinetics, Efficacy and Safety of the 304 Injection | ||
| NCT05528679 | A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma | ||
| NCT06099652 | Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease | ||
| NCT06242652 | A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) | ||
| NCT06412471 | A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | ||
| NCT04151407 | The Study of Drug 601 in Patients With Diabetic Macular Edema (DME) | ||
| NCT06533605 | Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors | ||
| NCT04667897 | 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) | ||
| NCT03950297 | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A | ||
| NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | ||
| NCT06222671 | A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) | ||
| NCT05604898 | A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis | ||
| NCT03998345 | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China | ||
| NCT06680947 | A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | ||
| NCT04468997 | The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD) | ||
| NCT05520177 | A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss | ||
| NCT06554847 | Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis | ||
| NCT04466254 | Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer | ||
| NCT04922151 | 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV) |
